Now Reading: Emcure Pharma Q1 profit rises 42%, Satish Mehta named chairman
-
01
Emcure Pharma Q1 profit rises 42%, Satish Mehta named chairman
Emcure Pharma reported a 42% year on year rise in net profit to Rs 294 crore for the June quarter of FY27, up from Rs 207 crore a year earlier, according to…
Emcure Pharma reported a 42% year on year rise in net profit to Rs 294 crore for the June quarter of FY27, up from Rs 207 crore a year earlier, according to NDTV Profit. Revenue rose 22.8% to Rs 2,580 crore, while EBITDA increased 27.8% to Rs 533 crore, up from Rs 417 crore, with the EBITDA margin expanding 90 basis points to 20.7%. The company's board separately appointed chief executive Satish Mehta as chairman. Emcure, founded in 1981 by Mehta, is a Pune based pharmaceutical company operating in more than 70 countries, including markets in Europe and Canada, with a portfolio spanning gynaecology, cardiology, oncology and HIV and AIDS treatments, alongside capabilities in biologics, active pharmaceutical ingredients and iron formulations.
Indian Opinion Analysis
Revenue grew 22.8% alongside the profit and EBITDA gains, with the EBITDA margin expanding to 20.7% from 19.8% a year earlier. The board's appointment of chief executive Satish Mehta, who founded Emcure in 1981, as chairman comes with no stated reason in the report. Emcure's spread across more than 70 countries and therapeutic areas from gynaecology to oncology and HIV and AIDS treatment gives the growth some geographic and product breadth. The next quarterly report will show whether the 20.7% EBITDA margin holds.
Source: ndtvprofit.com
This brief was synthesised by AI from the source linked above.
